870316 | N-hexadecyl-pSar25

N-Hexadecyl polysarcosine-25


Powder

Size SKU Packaging Price
25mg 870316P-25mg 870316P-25mg 1 x 25mg $395.00
Base Price: ${originalprice|money}
Custom Packaging: (${concentration} @$4.00/ea. + $100) ${custompackagingtotal|money}
Packaging: ${concentration}
Item Total: ${totalprice|money}
(Sales Tax may apply)
Please select an option above.
${sku} - ${concentration}

N-hexadecyl-pSar25

N-hexadecyl-pSar25

N-Hexadecyl polysarcosine-25

Polymeric lipids have long been used in the pharmaceutical industry as stealth coating agents, most notably PEGylated lipids. When formulated into lipid nanoparticles (LNPs), PEGylated lipids have shown improved circulation times and particle pharmacokinetics. However, there are some negatives associated with PEGylated lipids - decrease in transfection potency and production of anti-PEG antibodies. Due to these drawbacks, there has been much effort towards finding alternatives to PEGylated lipids.

One promising alternative to PEGylated lipids is a polypeptoid-lipid conjugate based on the amino acid sarcosine (pSar). pSar lipids of varying polymeric chain lengths have been used to tune physical properties of LNPs such as particle size, morphology, and internal structure. pSar LNPs have also proven to be an excellent mRNA transfection agent. Comparing pSar LNPs to PEGylated LNPs showed a more robust mRNA transfection potency while also improving the safety profile (Nogueira, S. et al., 2020). 

Hygroscopic
No
Light Sensitive
No
Molecular Formula

C91H160N26O25

Percent Composition

C 54.15%, H 7.99%, N 18.04%, O 19.82%

Purity
>99%
Stability
1 Year
Storage Temperature
-20°C
CAS Number
120468-76-0
CAS Registry Number is a Registered Trademark of the American Chemical Society
Formula Weight
2018.440
Exact Mass
2017.200

Sara S. Nogueira, Anne Schlegel, Konrad Maxeiner, Benjamin Weber, Matthias Barz, Martin A. Schroer, Clement E. Blanchet, Dmitri I. Svergun, Srinivas Ramishetti, Dan Peer, Peter Langguth, Ugur Sahin, and Heinrich Haas. ACS Applied Nano Materials 2020 3 (11), 10634-10645. DOI: 10.1021/acsanm.0c01834